Will that Be One Dose or Two? U.S. Buying 100 Million More Doses of Johnson & Johnson’s One-Shot Vaccine

Sure, it has slightly lower efficacy than the Pfizer (PFE) and Moderna (MRNA) vaccines, but the Johnson & Johnson (JNJ) shot has the incredible advantage of not requiring a second shot.

With America so torn on the merits and health risks of the two-shot vaccine, there are lots of people who would like the single-shot solution. And as it turns out, the U.S. government agrees.

On Wednesday, according to a White House official, the United States said it plans to double its order of the single-shot Johnson & Johnson coronavirus vaccine, procuring an additional 100 million doses.

The United States has already paid over $1 billion for 100 million doses from J&J and had an option to purchase an additional 200 million doses. Something tells us, another round of 100 million doses is not too far away, especially considering Biden’s pledge to speed up the vaccination process and taking down a virus that has killed more than 528,000 people in the U.S. alone.

J&J’s manufacturing has been slower than expected, and the company was not expected to be able to deliver any doses of its vaccine this week.

As of Tuesday morning, more than 123 million doses of the coronavirus vaccines had been distributed in the United States and 93.7 million shots had been administered, according to data from the U.S. Centers for Disease Control and Prevention (CDC).

Originally published by Reuters.com

Add Comment

Market Overview

Leave a Reply

Your email address will not be published. Required fields are marked *